However, in breast cancer, the prevalence of p53 mutations varies depending on the subtypes of the disease, being present in roughly 80% of TNBC, 10% of luminal A disease, 30% of luminal B disease, and 70% of HER2-enriched disease [11,12,13]. Here, ERBB2 is linked to breast cancer.